Stocktoria
MANGOCEUTICALS, INC. MGRX
MANGOCEUTICALS, INC. (MGRX) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $456,021 at a -4526.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.041 |
| Retained earnings / assets | -2.526 |
| EBIT / assets | -1.121 |
| Equity / liabilities | 17.068 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
About MANGOCEUTICALS, INC.
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
FAQ
Is MGRX financially healthy?
MANGOCEUTICALS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does MGRX pay a dividend?
No, MANGOCEUTICALS, INC. does not currently pay a dividend.
How profitable is MGRX?
In FY2025, MANGOCEUTICALS, INC. had a net margin of -4526.8% and a return on equity of -135.8%.
Is MGRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MANGOCEUTICALS, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.